≥18yrs: Initially 75mg/day in 2–3 divided doses; may increase at 4-day intervals in 75mg/day increments to 150mg/day; max 375mg/day, in 3 divided doses. Mild-to-moderate renal impairment: reduce by at least 25%; hemodialysis: reduce by 50% (hold dose until end of dialysis treatment). trimester; see full labeling for effects on neonate). Increased risk of serotonin syndrome with concomitant other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. The recommended starting dose for Effexor is 75 mg/day, administered in two or three divided doses, taken with food. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Concomitant weht loss agents (eg, phentermine), serotonin precursors (tryptophan supplements): not recommended.
Effexor adult dose
Withdraw gradually (reduce by 75mg/day at 1-week intervals). During or within 14 days of MAOIs (see Interactions). Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Immediate release 25-50 mg/day PO divided q8-12hr initially; may be increased as tolerated by ≤25 mg/day no faster than every 4 days Moderate: Up to 225 mg/day PO divided q8-12hr Severe: Up to 375 mg/day PO divided q8-12hr Extended release 37.5 mg PO once daily initially; may be increased by 37.5 mg/day every 4-7 days; not to exceed 225 mg/day Headache (25-38%) Nausea (21-58%) Insomnia (15-24%) Asthenia (16-20%) Dizziness (11-24%) Ejaculation disorder (2-19%) Somnolence (12-26%) Dry mouth (12-22%) Diaphoresis (7-19%) Anorexia (15-17%) Nervousness (17-26%) Anorgasmia (5-13%) Weht loss (1-6%) Abnormal vision (4-6%) Hypertension (2-5%) Impotence (4-6%) Paresthesia (2-3%) Tremor (1-10%) Vasodilation (2-6%) Vomiting (3-8%) Weht gain (2%) Flatulence (3-4%) Pruritus (1%) Yawning (3-8%) Dyspepsia (5-7%) Twitching (1-3%) Mydriasis (2%) 65 years Not FDA approved for children; in children and young adults; benefits of taking antidepressants must be wehed against risks Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments Patient’s family should communicate any abrupt behavioral changes to healthcare provider Worsening behavior and suicidal tendencies that are not part of presenting symptoms may necessitate discontinuance of therapy Not FDA approved for treatment of bipolar depression Risk of mydriasis; may trger angle closure attack in patients with angle closure glaucoma with anatomiy narrow angles without a patent iridectomy Use caution in bipolar mania, history of seizures, and cardiovascular disease May precipitate mania or hypomania episodes in patients with bipolar disorder; avoid monotherapy in bipolar disorder; screen patients presenting with depressive symptoms for bipolar disorder Use caution in hepatic or renal impairment Neonates exposed to serotonin-norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) late in 3rd trimester of pregnancy have developed complications necessitating prolonged hospitalization, respiratory support, and tube feeding Clinical worsening and suicidal ideation may occur despite medication in adolescents and young adults (18-24 years) When discontinuing, taper dosage to avoid flulike symptoms May cause increase in nervousness, anxiety, or insomnia May impair ability to operate heavy machinery; depresses CNS Bone fractures reported with antidepressant therapy; consider possibility if patient experiences bone pain May cause snificant increase in serum cholesterol Dose-dependent anorectic effects and weht loss reported in children and adult patients Dose-related increase in systolic and diastolic pressure reported Eosinophilic pneumonia and interstitial lung disease reported SAIDH and hyponatremia reported SSRIs Potentially life-threatening serotonin syndrome with SSRIs and SNRIs when used in combination with other serotonergic agents including TCAs, buspirone tryptophan, fentanyl, tramadol, lithium, and triptans; symptoms include tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features resembling neuroleptic malnant syndrome, seizures, ridity, autonomic instability with possible rapid fluctuations of vital sns, and mental status changes that include extreme agitation progressing to delirium and coma Venlafaxine in patient being treated with linezolid or IV methylene blue increases risk of serotonin syndrome; if linezolid or IV methylene blue must be administered, discontinue venlafaxine immediately and monitor for central nervous system (CNS) toxicity; therapy may be resumed 24 hours after last linezolid or methylene blue dose or after 2 weeks of monitoring, whichever comes first SSRIs and SNRIs may impair platelet aggregation and increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and GI hemorrhage to life-threatening hemorrhage; concomitant use of aspirin, NSAIDs, warfarin, other anticoagulants, or other drugs known to affect platelet function may add to this risk Control hypertension before initiating treatment; monitor blood pressure regularly during treatment Risks of sustained hypertension, hyponatremia, and impeded heht and weht in children Drug-laboratory test interactions: False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been observed during venlafaxine therapy because of lack of specificity of the screening tests May cause or exacerbate sexual dysfunction "Bicyclic" antidepressant; drug is structurally unrelated to SSRIs, MAOIs, and tricyclic antidepressants (TCAs), but it and its metabolite are potent inhibitors of serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake; it does not have MAOI activity or activity for H1 histaminergic, muscarinic cholinergic, or alpha2-adrenergic receptors The above information is provided for general informational and educational purposes only.
Pre-existing hypertension, cardio- or cerebrovascular disease. Monitor BP before and during treatment; consider dose reduction or discontinuation if elevated BP persists.
Effexor adult dose
Effexor adult dose
Applies to the following strength(s): 25 mg ; 50 mg ; 75 mg ; 100 mg ; 37.5 mg ; 150 mg ; 225 mg The information at is not a substitute for medical advice. Immediate release: Initial dose: 37.5 mg orally twice a day or 25 mg orally 3 times a day Maintenance dose: May increase in daily increments of up to 75 mg orally at intervals of no less than 4 days Maximum dose: (moderately depressed outpatients): 225 mg orally per day Maximum dose (severely depressed inpatients): 375 mg orally per day Comments: -Daily dosage may be divided in 2 or 3 doses/day Extended release: Initial dose: 75 mg orally once a day Maintenance dose: May increase in daily increments of up to 75 mg orally at intervals of no less than 4 days Maximum dose (moderately depressed outpatients): 225 mg orally per day Maximum dose (severely depressed inpatients): 375 mg orally per day Use: Treatment of major depressive disorder (MDD) Extended release: Initial dose: 75 mg orally once a day Maintenance dose: May increase in daily increments of 75 mg orally at intervals of no less than 4 days Maximum dose: 225 mg orally per day Uses: -Treatment of Generalized Anxiety Disorder (GAD) -Treatment of Social Anxiety Disorder (SAD) Extended release: Initial dose: 37.5 mg orally once a day Maintenance dose: May increase dose in daily increments of 75 mg orally at intervals of no less than 7 days Maximum dose: 225 mg orally per day Use: Treatment of Panic Disorder (PD), with or without agoraphobia -Mild to moderate renal impairment (Cr Cl 30 to 89 m L/min): Dosage should be reduced by 25% to 50% -Mild to moderate hepatic impairment: Dosage should be reduced 50%. Each capsule should be swallowed whole with fluid and not divided, crushed, chewed, or placed in water or it may be administered by carefully opening the capsule and sprinkling the entire contents on a spoonful of applesauce.
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. ATARAX ANXIETY
Effexor adult dose:
Rating: 100 / 100
Overall: 98 Rates